Small-cap biotech delivered a run of clinical and commercial progress, headlined by Oxford BioDynamics' first Gulf region partnership for its prostate cancer test. Crism Therapeutics cleared a key procedural hurdle ahead of patient recruitment for its glioblastoma trial, while Arecor Therapeutics saw peer-reviewed validation of its concentrated insulin candidate.
Oxford BioDynamics lands first Gulf partnership for prostate test
Oxford BioDynamics (AIM:OBD) has signed a partnership agreement with The Dubai London Clinics & Hospitals Group, one of Dubai's longest-established private healthcare providers, marking the company's first commercial deal for its EpiSwitch PSE prostate cancer test in the Gulf region. Oxford BioDynamics, trading at 0.13p, develops precision diagnostic tests built on its EpiSwitch Orion cloud-based 3D genomics platform, which is already used by pharma and biotech partners globally. The agreement brings the test into DLCH's network of five UAE facilities, including the ACHS-accredited Dubai London Hospital in Jumeirah.
Under the arrangement, patient blood samples will be collected at DLCH sites and shipped to Oxford BioDynamics' UK laboratory for processing, with the end-to-end workflow already validated between the two organisations ahead of the announcement. The companies now intend to work jointly on driving adoption across DLCH's clinician network, including local market development and engagement with regional payers, with test volumes expected to build as that push gets under way. Further details on the partnership are due to be announced jointly by the two parties in due course.
"We're delighted to be partnering with DLCH to make EpiSwitch PSE available across its facilities in the UAE. This is our first commercial partnership for the test in the Gulf region and an important milestone as we continue to expand internationally," said Richard Compton, Chief Executive Officer, Oxford Biodynamics.
The deal matters because it demonstrates that demand for EpiSwitch PSE extends well beyond the US market, where Oxford BioDynamics already has a contract sales partnership in place to accelerate prostate cancer test adoption. Establishing a validated sample-collection-to-processing pipeline with a well-regarded regional operator gives the company a template it can replicate with other international healthcare groups, turning a single-market diagnostic into a platform with genuine multi-territory reach, a distinction that matters for a company whose commercial credibility has previously rested almost entirely on domestic progress.
Crism Therapeutics clears site setup for glioblastoma trial
Crism Therapeutics Corporation (AIM:CRTX) said the Site Initiation Visit at its lead NHS clinical trial site has been completed successfully, clearing the procedural gateway needed to begin screening and enrolling patients. Shares in the UK-based drug delivery specialist rose 7.5% to 10.75p on the update. Crism is developing localised, sustained-release chemotherapy treatments, and is now working with the clinical site, the NHS Trust and its clinical partners to begin enrolling patients in the coming weeks.
The trial in question is a Phase II study of irinotecan ChemoSeed, Crism's proprietary implant designed to deliver irinotecan directly into the tumour margin following surgical removal of a glioblastoma tumour. Site initiation confirms that the trial site has regulatory and ethical sign-off to begin screening and enrolling patients, a step that typically follows extensive administrative and logistical preparation between sponsor and site.
Clearing this gateway removes one of the last operational barriers between Crism and first patient data in its lead NHS study, shortening the runway to a trial readout that will be the first real test of ChemoSeed's clinical potential in glioblastoma, a cancer with historically poor treatment options and high unmet need.
Arecor's AT278 diabetes data published in peer-reviewed journal
Arecor Therapeutics (AIM:AREC), trading at 59.5p, said data from its AT278-104 study has been published in the peer-reviewed journal Diabetes, Obesity & Metabolism. The Cambridge-based clinical stage biotech develops therapeutics aimed at reducing treatment burden for people with diabetes, obesity and other cardiometabolic diseases, and the study evaluated AT278, an ultra-concentrated U500 insulin aspart formulation, against standard U100 insulin aspart and U500 human regular insulin.
AT278 showed significantly faster insulin absorption than both comparator formulations, producing a greater glucose-lowering effect within the first hour after administration. Notably, that ultra-rapid onset held regardless of patient body mass index, a distinction from standard insulin aspart and a challenge that has long dogged concentrated insulin therapies. Overall insulin exposure and glucose-lowering activity remained comparable across the formulations tested, with a favourable safety profile reported throughout.
Peer-reviewed publication gives Arecor's data an independent stamp of scientific scrutiny that internal trial readouts alone cannot provide, strengthening the evidence base as the company looks to advance AT278 toward later-stage development and partnering discussions in a concentrated insulin market where dosing convenience and consistent absorption across patient types remain key differentiators.
